PL366006A1 - Izoindolin-1-onowe aktywatory glukokinazy - Google Patents

Izoindolin-1-onowe aktywatory glukokinazy

Info

Publication number
PL366006A1
PL366006A1 PL01366006A PL36600601A PL366006A1 PL 366006 A1 PL366006 A1 PL 366006A1 PL 01366006 A PL01366006 A PL 01366006A PL 36600601 A PL36600601 A PL 36600601A PL 366006 A1 PL366006 A1 PL 366006A1
Authority
PL
Poland
Prior art keywords
isoindolin
glucokinase activators
glucokinase
activators
diabetes
Prior art date
Application number
PL01366006A
Other languages
English (en)
Inventor
Kevin Richard Guertin
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL366006A1 publication Critical patent/PL366006A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
PL01366006A 2000-12-13 2001-12-07 Izoindolin-1-onowe aktywatory glukokinazy PL366006A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25527300P 2000-12-13 2000-12-13
US31871501P 2001-09-13 2001-09-13
PCT/EP2001/014404 WO2002048106A2 (en) 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators

Publications (1)

Publication Number Publication Date
PL366006A1 true PL366006A1 (pl) 2005-01-24

Family

ID=26944583

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366006A PL366006A1 (pl) 2000-12-13 2001-12-07 Izoindolin-1-onowe aktywatory glukokinazy

Country Status (35)

Country Link
US (1) US6482951B2 (pl)
EP (1) EP1349856B1 (pl)
JP (1) JP4021766B2 (pl)
KR (1) KR100520651B1 (pl)
CN (1) CN1247574C (pl)
AT (1) ATE297922T1 (pl)
AU (2) AU3841502A (pl)
BG (1) BG107903A (pl)
BR (1) BR0116169A (pl)
CA (1) CA2430579C (pl)
CY (1) CY1105587T1 (pl)
CZ (1) CZ20031882A3 (pl)
DE (1) DE60111570T2 (pl)
DK (1) DK1349856T3 (pl)
EG (1) EG24358A (pl)
ES (1) ES2243578T3 (pl)
HR (1) HRP20030450B1 (pl)
HU (1) HUP0400587A3 (pl)
IL (2) IL156264A0 (pl)
MA (1) MA26973A1 (pl)
MX (1) MXPA03005170A (pl)
MY (1) MY136741A (pl)
NO (1) NO325810B1 (pl)
NZ (1) NZ526236A (pl)
PA (1) PA8534601A1 (pl)
PE (1) PE20020593A1 (pl)
PL (1) PL366006A1 (pl)
PT (1) PT1349856E (pl)
RS (1) RS50933B (pl)
RU (1) RU2249590C2 (pl)
SI (1) SI1349856T1 (pl)
SK (1) SK8732003A3 (pl)
TW (1) TWI294876B (pl)
UY (1) UY27069A1 (pl)
WO (1) WO2002048106A2 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
MXPA05003559A (es) 2002-10-03 2005-06-03 Novartis Ag (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2.
PT1549638E (pt) 2002-10-03 2007-12-11 Hoffmann La Roche Indole-3-cabboxamidas como activantes da glucoquinase
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
EP1594863A1 (en) * 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
AU2005229416B2 (en) 2004-04-02 2009-03-26 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
KR20070006816A (ko) * 2004-04-02 2007-01-11 노파르티스 아게 티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
EP1921074A1 (en) * 2005-08-31 2008-05-14 Astellas Pharma Inc. Thiazole derivative
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
US8796313B2 (en) 2005-11-01 2014-08-05 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
WO2007053765A2 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
WO2007053662A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
CA2627813A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
JP2009514835A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5386350B2 (ja) * 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
JP5419706B2 (ja) * 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
MX2009009525A (es) * 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
TW200934772A (en) * 2008-01-15 2009-08-16 Lilly Co Eli Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
KR20100110367A (ko) * 2008-01-24 2010-10-12 메르크 파텐트 게엠베하 당뇨병 치료를 위한 베타-아미노산 유도체들
HRP20150842T1 (hr) * 2008-04-28 2015-09-11 Kyorin Pharmaceutical Co., Ltd. Derivati ciklopentilakrilamida
EA018988B1 (ru) 2008-05-16 2013-12-30 Такеда Калифорния, Инк. Активаторы глюкокиназы
PE20110303A1 (es) * 2008-09-11 2011-05-21 Pfizer Derivados de heteroaril acetamidas como activadores de glucoquinasa
EP2553086B1 (en) 2010-03-31 2017-04-19 The Scripps Research Institute Reprogramming cells
US8178689B2 (en) * 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
RU2693698C2 (ru) * 2013-05-27 2019-07-04 Ф. Хоффманн-Ля Рош Аг Новые соединения 3,4-дигидро-2н-изохинолин-1-она и 2,3-дигидроизоиндол-1-она
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN116283717B (zh) * 2023-01-06 2025-04-08 暨南大学 一种藁本内酯衍生物及其制备方法和应用
WO2024229228A2 (en) * 2023-05-02 2024-11-07 The Rockefeller University 1-oxoisoindolin-2-yl amide activators of vcp and derivatives thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687147A1 (fr) * 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
JP3314938B2 (ja) * 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
CZ301366B6 (cs) 1999-03-29 2010-02-03 F. Hoffmann-La Roche Ag 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem
AU5227001A (en) 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators
EP1282611B1 (en) 2000-05-08 2004-10-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators

Also Published As

Publication number Publication date
IL156264A (en) 2010-11-30
CA2430579C (en) 2010-01-26
RU2249590C2 (ru) 2005-04-10
HUP0400587A3 (en) 2011-03-28
BG107903A (bg) 2004-02-27
PA8534601A1 (es) 2002-08-26
US20020082260A1 (en) 2002-06-27
HRP20030450A2 (en) 2005-04-30
BR0116169A (pt) 2003-12-23
HRP20030450B1 (en) 2006-02-28
WO2002048106A3 (en) 2002-11-28
WO2002048106A2 (en) 2002-06-20
PE20020593A1 (es) 2002-07-06
EP1349856A2 (en) 2003-10-08
AU3841502A (en) 2002-06-24
KR20030064817A (ko) 2003-08-02
EP1349856B1 (en) 2005-06-15
PT1349856E (pt) 2005-09-30
CA2430579A1 (en) 2002-06-20
DE60111570D1 (de) 2005-07-21
DK1349856T3 (da) 2005-10-17
UY27069A1 (es) 2002-07-31
NO20032674D0 (no) 2003-06-12
CN1247574C (zh) 2006-03-29
IL156264A0 (en) 2004-01-04
AU2002238415B2 (en) 2007-01-04
ATE297922T1 (de) 2005-07-15
NO325810B1 (no) 2008-07-21
RS50933B (sr) 2010-08-31
ES2243578T3 (es) 2005-12-01
KR100520651B1 (ko) 2005-10-11
YU47703A (sh) 2006-05-25
SK8732003A3 (en) 2004-04-06
JP4021766B2 (ja) 2007-12-12
CZ20031882A3 (cs) 2003-12-17
DE60111570T2 (de) 2006-05-11
MXPA03005170A (es) 2003-09-22
MY136741A (en) 2008-11-28
MA26973A1 (fr) 2004-12-20
SI1349856T1 (en) 2005-10-31
JP2004521095A (ja) 2004-07-15
CY1105587T1 (el) 2010-07-28
EG24358A (en) 2009-03-04
CN1481382A (zh) 2004-03-10
US6482951B2 (en) 2002-11-19
HK1063314A1 (en) 2004-12-24
NZ526236A (en) 2004-12-24
TWI294876B (en) 2008-03-21
HUP0400587A2 (hu) 2004-06-28
NO20032674L (no) 2003-06-12

Similar Documents

Publication Publication Date Title
EG24358A (en) Isoindolin-1-one glucokinase avtivators
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
CA2499329A1 (en) Indole-3-carboxamides as glucokinase (gk) activators
MY136926A (en) Glucokinase activators
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
WO2001083465A3 (en) Alkynyl phenyl heteroaromatic glucokinase activators
JO2180B1 (en) Glucokinase Trans olivine steroids
MXPA03003870A (es) Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
PT1282611E (pt) Fenilacetamidas substituidas e sua utilizacao como activadores da glucocinase
AU2002213925A1 (en) Use of glp-1 and flp-2 peptides for treatment of bone disorders
ZA200407986B (en) Substituted phenylacetamides and their use as glucokinase activators.
UA84025C2 (en) Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS
MY142777A (en) Substituted indole-o-glucosides
UA86042C2 (en) Substituted indazole-o-glucosides
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
JO2238B1 (en) Glycine stimulants iswindline 1- on
EP1251847A4 (en) NEW USE OF PRODIGIOSINE TO TREAT DIABETES
AU2003278974A1 (en) Dental application device
UA70017A (en) Method for conservative treatment of chronic tonsillitis in adults
UA42301A (uk) Засіб "камілаль" для лікування і профілактики проктологічних захворювань
UA32466C2 (uk) Комплексний інфузійний препарат "реосорбілакт"
MXPA04003673A (es) Uso de aplidina para el tratamiento de cancer pancreatico.

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)